AAWH Ascend Wellness Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756390 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-10.9%
TTM net income YoY-39.1%
TTM EPS YoY-45.0%
Revenue 3-yr CAGR7.2%
Net income 3-yr CAGR—
Margins
Gross margin33.9%
Operating margin-3.4%
Net margin-23.6%
FCF margin2.4%
EBITDA margin8.2%
Returns
ROE-1,004.3%
ROA-13.1%
ROIC (approx.)-6.1%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets105.1%
Debt / equity—
Current ratio1.92x
Interest coverage-0.33x
Cash quality & payout
Operating cash flow / net income-0.32x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $500.58M | $561.60M |
| Cost of revenue | $330.90M | $377.39M |
| Gross profit | $169.68M | $184.21M |
| SG&A expense | $169.69M | $179.48M |
| Operating income | -$17.01M | $4.73M |
| Interest expense | $51.29M | $45.26M |
| Pretax income | -$66.81M | -$39.82M |
| Income tax | $51.38M | $45.17M |
| Net income | -$118.19M | -$84.99M |
| EBITDA | $56.52M | $70.89M |
| EPS (basic) | -0.58 | -0.40 |
| EPS (diluted) | -0.58 | -0.40 |
| Weighted avg. shares (diluted) | 203.48M | 212.43M |
| Balance sheet | ||
| Cash & equivalents | $85.68M | $88.25M |
| Receivables | $27.02M | $36.54M |
| Inventory | $84.71M | $89.55M |
| Current assets | $208.95M | $229.38M |
| PP&E, net | $382.40M | $260.46M |
| Goodwill | $58.45M | $49.60M |
| Intangibles | $196.07M | $205.50M |
| Total assets | $907.93M | $900.43M |
| Current liabilities | $109.01M | $144.54M |
| Short-term debt | $10.37M | $72.69M |
| Long-term debt | $291.10M | $214.42M |
| Total debt | $301.47M | $287.11M |
| Total liabilities | $954.55M | $828.63M |
| Shareholders' equity | -$47.44M | $70.98M |
| Net debt | $215.80M | $198.86M |
| Shares outstanding | 202.22M | 205.03M |
| Cash flow statement | ||
| Operating cash flow | $38.05M | $73.29M |
| Capital expenditure | $26.01M | $22.53M |
| Free cash flow | $12.04M | $50.76M |
| Investing cash flow | -$45.74M | -$37.20M |
| Financing cash flow | $5.11M | -$20.35M |
| Depreciation & amortization | $73.53M | $66.16M |
| Stock-based compensation | $2.45M | $18.61M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.